Form 4: Edwards Lifesciences Exec Sells Shares for Tax

Edwards Lifesciences SVP, Corporate Controller Andrew M. Dahl disposed of 176 shares of common stock to cover tax liabilities.

Summary

• Andrew M. Dahl, SVP, Corporate Controller at Edwards Lifesciences Corp, reported a change in beneficial ownership.
• On February 22, 2026, Dahl disposed of 176 shares of common stock.
• The shares were disposed of at a price of $79.78 per share.
• This transaction was coded as 'F', indicating a disposition to the issuer to pay tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security or an equity settlement of a derivative security.
• Following this transaction, Dahl directly beneficially owns 9,089.4805 shares of Edwards Lifesciences common stock.
• The filing notes that it reflects changes in beneficial ownership only and does not identify other securities beneficially owned by the Reporting Person, also mentioning the inclusion of quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine disposition of shares for tax purposes by an executive, which typically carries no significant positive or negative implications for the company's operational or financial health.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those for tax purposes (Transaction Code F), are common and generally not indicative of management's discretionary view on the company's future prospects. These are often pre-scheduled events related to the vesting of equity awards.

Related Party Transactions

• Andrew M. Dahl disposed of 176 shares of common stock to Edwards Lifesciences Corp to satisfy tax withholding obligations related to equity compensation.

Stakeholder Impact

• Shareholders: Minimal impact, as the transaction is a routine, non-discretionary sale of a small number of shares for tax purposes and does not reflect a change in company fundamentals or executive confidence.

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary sale of a small number of shares by an executive to cover tax obligations. Such transactions are common and do not typically reflect a change in the executive's confidence in the company or its future prospects. Therefore, it provides no new information that would warrant a change from a 'hold' recommendation.

Keywords

Edwards Lifesciences, EW, Form 4, Insider Transaction, Stock Sale, Corporate Controller, Andrew M. Dahl, Tax Liability